News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS), Global Alliance For TB Drug Development Link Up To Search For TB Cure



8/20/2014 6:05:59 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Novartis Provides Drug Candidate Compounds To TB Alliance

Exclusive Worldwide License From Novartis Includes A Novel Class Of Drugs That Is Active Against Drug Sensitive And Multi-Resistant Strains Of Tuberculosis

Basel, August 20, 2014 - Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance) for compounds to fight tuberculosis (TB) that have been discovered at the Novartis Institutes for Tropical Diseases (NITD).

According to the World Health Organization, there are more than 8.6 million cases of tuberculosis each year, with more than 1.3 million deaths reported annually. TB is a global disease, but has its deadliest impact in resource-poor countries.[1] Current therapies for TB require 6-30 month dosing regimes and there are increasingly drug resistant strains of TB emerging.[2]

"TB is one of the scourges of the developing world and new medicines are desperately needed to combat its continued spread," said Mark C. Fishman, President of Novartis Institutes for BioMedical Research. "TB Alliance is well placed to take our discoveries and compounds through development for the benefit of patients with TB."

"Our long-standing partnership with Novartis gives us confidence in the scientific underpinnings of the TB portfolio," says Mel Spigelman, MD, President and CEO of TB Alliance. "We look forward to advancing the most promising compounds into the clinic to meet the urgent need for new TB treatments."

Under the terms of agreement, NITD will fully transfer its TB research and development program to TB Alliance, which will take financial and operational responsibility for continued research, development, approval and distribution of compounds in the portfolio. Included is a novel class of drugs called indolcarboxamides that are active against drug sensitive and multi-resistant strains of TB. One of these preclinical compounds NITD304, blocks MmpL3, a protein essential for the TB bacterium's survival. NITD304 was described last year in a paper published in Science Translational Medicine.[3]

Novartis has collaborated in the past with TB Alliance and believes it has the best combination of expertise, capacity, and strategic interest to develop new agents and regimens for TB.

Novartis efforts in discovery of medicines specifically for the developing world continues, especially focused now on new therapies for treating parasitic diseases such as malaria, and human African trypanosomiasis (HAT) - also known as sleeping sickness, as well as viral disease such as dengue fever.

Disclaimer
This press release contains expressed or implied forward-looking statements, including statements that can be identified by terminology such as "look forward to," "will," "continues," or similar expressions. Such forward-looking statements reflect the current views of the Group regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such statements. These expectations could be affected by, among other things, risks and factors referred to in the Risk Factors section of Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update it in the future.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 136,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis.

References
[1] Global Tuberculosis Report 2013, World Health Organization,
http://www.who.int/tb/publications/global_report/gtbr13_executive_summary.pdf?ua=1
[2] CDC, Treatment of Tuberculosis, http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm
[3] Ujjini H. Manjunatha, Science Translational Medicine, Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis ,

Novartis Media Relations
Central media line : +41 61 324 2200 Eric Althoff Novartis Global Media Relations
+41 61 324 7999 (direct)
+41 79 593 4202 (mobile)
eric.althoff@novartis.com

Mariellen Gallagher
Novartis Institutes for BioMedical Research
+ 1 617 871 7665
+ 1 617 909 9137(mobile)
mariellen.gallagher@novartis.com

e-mail: media.relations@novartis.com

For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis For questions about the site or required registration, please contact: journalisthelp@thenewsmarket.com.

Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944
Pierre-Michel Bringer +41 61 324 1065
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188

North America:
Stephen Rubino +1 862 778 8301
Susan Donofrio +1 862 778 9257

e-mail: investor.relations@novartis.com e-mail: investor.relations@novartis.com

Hey, check out all the research scientist jobs. Post your resume today!

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES